This report describes and explains the immunohematology market and covers 2019-2024, termed the historic period, and 2024-2029, 2034F termed the forecast period. The report evaluates the market across each region and for the major economies within each region.
The global immunohematology market reached a value of nearly $2.45 billion in 2024, having grown at a compound annual growth rate (CAGR) of 3.24% since 2019. The market is expected to grow from $2.45 billion in 2024 to $3.17 billion in 2029 at a rate of 5.24%. The market is then expected to grow at a CAGR of 4.83% from 2029 and reach $4.1 billion in 2034.
Growth in the historic period resulted from the increasing prevalence of blood disorders, increase in infectious diseases, expanding healthcare expenditure, rise in trauma and accident cases and favorable government initiative and funding. Factors that negatively affected growth in the historic period were lack of skilled personnel.
Going forward, increasing organ transplants and surgeries, emergence of personalized medicine, growing aging population and strong economic growth will drive the growth. Factor that could hinder the growth of the immunohematology market in the future include limited blood supply.
The global immunohematology market is fairly concentrated, with large players operating in the market. The top ten competitors in the market made up to 36.89% of the total market in 2023. QuidelOrtho Corporation (Ortho-Clinical Diagnostics) was the largest competitor with a 6.94% share of the market, followed by Abbott Laboratories. with 6.63%, Grifols S.A. with 6.25%, BIO-RAD LABORATORIES, INC. with 5.72%, Beckman Coulter Inc. (Danaher Corporation). with 4.81%, BECTON, DICKINSON AND COMPANY with 2.59%, Cardinal Health Inc. with 1.06%, Siemens Healthineers. with 1.03%, F. Hoffmann-La Roche AG with 1.00% and Sysmex Corporation. with 0.85%.
North America was the largest region in the immunohematology market, accounting for 39.72% or $976.68 million of the total in 2024. It was followed by Asia Pacific, Western Europe and then the other regions. Going forward, the fastest-growing regions in the immunohematology market will be Asia Pacific and Western Europe where growth will be at CAGRs of 5.69% and 5.43% respectively. These will be followed by North America and South America where the markets are expected to grow at CAGRs of 5.31% and 4.93% respectively.
The immunohematology market is segmented by product into analyzers and systems and reagents. The reagents market was the largest segment of the immunohematology market segmented by product, accounting for 59.02% or $1.45 billion of the total in 2024. Going forward, the analyzers and systems segment is expected to be the fastest growing segment in the immunohematology market segmented by product, at a CAGR of 5.48% during 2024-2029.
The immunohematology market is segmented by technology into biochips, erythrocyte-magnetized technology (Emt), gel cards, microplates, polymerase chain reaction (PCR) and other technologies. The polymerase chain reaction (PCR) market was the largest segment of the immunohematology market segmented by technology, accounting for 32.91% or 809.03 million of the total in 2024. Going forward, the biochips segment is expected to be the fastest growing segment in the immunohematology market segmented by technology, at a CAGR of 7.21% during 2024-2029.
The immunohematology market is segmented by disease into blood-related diseases, HIV (Human immunodeficiency viruses) and hepatitis. The blood-related diseases market was the largest segment of the immunohematology market segmented by disease, accounting for 59.73% or $1.46 billion of the total in 2024. Going forward, the blood-related diseases segment is expected to be the fastest growing segment in the immunohematology market segmented by disease, at a CAGR of 5.79% during 2024-2029.
The immunohematology market is segmented by application into pretransfusion testing, investigation of immune hemolysis, perinatal testing, blood group phenotyping, leucocyte and platelet serology. The pretransfusion market was the largest segment of the immunohematology market segmented by application, accounting for 40.81% or $1.0 billion of the total in 2024. Going forward, the pretransfusion testing segment is expected to be the fastest growing segment in the immunohematology market segmented by application, at a CAGR of 5.77% during 2024-2029.
The immunohematology market is segmented by end user into blood banks, diagnostic and reference laboratories, hospitals and academic and research institutes. The hospitals market was the largest segment of the immunohematology market segmented by end user, accounting for 39.21% or $963.94 million of the total in 2024. Going forward, the hospitals segment is expected to be the fastest growing segment in the immunohematology market segmented by end user, at a CAGR of 5.67% during 2024-2029.
The top opportunities in the immunohematology markets segmented by product will arise in the reagents segment, which will gain $407.42 million of global annual sales by 2029. The top opportunities in the immunohematology market segmented by technology will arise in the polymerase chain reaction (PCR) segment, which will gain $310.72 million of global annual sales by 2029. The top opportunities in the immunohematology markets segmented by disease will arise in the blood-related diseases segment, which will gain $477.18 million of global annual sales by 2029. The top opportunities in the immunohematology markets segmented by application will arise in the pretransfusion testing segment, which will gain $324.77 million of global annual sales by 2029. The top opportunities in the immunohematology markets segmented by end user will arise in the hospitals segment, which will gain $306.08 million of global annual sales by 2029. The immunohematology market size will gain the most in USA at $241.59 million.
Market-trend-based strategies for the immunohematology market include focus on developing next-generation blood processing systems with cutting-edge automation and focus on transforming blood transfusion management with advanced multiplex analysis.
Player-adopted strategies in the immunohematology market include focus on enhancing its business capabilities through strategic partnerships and focus on strengthening its business operations through new launches.
To take advantage of the opportunities, the analyst recommends the immunohematology companies to focus on developing next-generation blood processing systems, focus on advancing multiplex blood testing technology, focus on the fastest-growing analyzers and systems segment, focus on biochips for accelerated growth, focus on blood-related diseases for market expansion, focus on pretransfusion testing to drive growth, expand in emerging markets, focus on expanding distribution channels for market growth, focus on developing competitive and value-based pricing strategies, focus on digital marketing strategies to enhance brand authority for immunohematology companies, focus on strategic partnerships with key opinion leaders to build credibility for immunohematology companies and focus on hospitals to drive growth in the immunohematology market.
The global immunohematology market reached a value of nearly $2.45 billion in 2024, having grown at a compound annual growth rate (CAGR) of 3.24% since 2019. The market is expected to grow from $2.45 billion in 2024 to $3.17 billion in 2029 at a rate of 5.24%. The market is then expected to grow at a CAGR of 4.83% from 2029 and reach $4.1 billion in 2034.
Growth in the historic period resulted from the increasing prevalence of blood disorders, increase in infectious diseases, expanding healthcare expenditure, rise in trauma and accident cases and favorable government initiative and funding. Factors that negatively affected growth in the historic period were lack of skilled personnel.
Going forward, increasing organ transplants and surgeries, emergence of personalized medicine, growing aging population and strong economic growth will drive the growth. Factor that could hinder the growth of the immunohematology market in the future include limited blood supply.
The global immunohematology market is fairly concentrated, with large players operating in the market. The top ten competitors in the market made up to 36.89% of the total market in 2023. QuidelOrtho Corporation (Ortho-Clinical Diagnostics) was the largest competitor with a 6.94% share of the market, followed by Abbott Laboratories. with 6.63%, Grifols S.A. with 6.25%, BIO-RAD LABORATORIES, INC. with 5.72%, Beckman Coulter Inc. (Danaher Corporation). with 4.81%, BECTON, DICKINSON AND COMPANY with 2.59%, Cardinal Health Inc. with 1.06%, Siemens Healthineers. with 1.03%, F. Hoffmann-La Roche AG with 1.00% and Sysmex Corporation. with 0.85%.
North America was the largest region in the immunohematology market, accounting for 39.72% or $976.68 million of the total in 2024. It was followed by Asia Pacific, Western Europe and then the other regions. Going forward, the fastest-growing regions in the immunohematology market will be Asia Pacific and Western Europe where growth will be at CAGRs of 5.69% and 5.43% respectively. These will be followed by North America and South America where the markets are expected to grow at CAGRs of 5.31% and 4.93% respectively.
The immunohematology market is segmented by product into analyzers and systems and reagents. The reagents market was the largest segment of the immunohematology market segmented by product, accounting for 59.02% or $1.45 billion of the total in 2024. Going forward, the analyzers and systems segment is expected to be the fastest growing segment in the immunohematology market segmented by product, at a CAGR of 5.48% during 2024-2029.
The immunohematology market is segmented by technology into biochips, erythrocyte-magnetized technology (Emt), gel cards, microplates, polymerase chain reaction (PCR) and other technologies. The polymerase chain reaction (PCR) market was the largest segment of the immunohematology market segmented by technology, accounting for 32.91% or 809.03 million of the total in 2024. Going forward, the biochips segment is expected to be the fastest growing segment in the immunohematology market segmented by technology, at a CAGR of 7.21% during 2024-2029.
The immunohematology market is segmented by disease into blood-related diseases, HIV (Human immunodeficiency viruses) and hepatitis. The blood-related diseases market was the largest segment of the immunohematology market segmented by disease, accounting for 59.73% or $1.46 billion of the total in 2024. Going forward, the blood-related diseases segment is expected to be the fastest growing segment in the immunohematology market segmented by disease, at a CAGR of 5.79% during 2024-2029.
The immunohematology market is segmented by application into pretransfusion testing, investigation of immune hemolysis, perinatal testing, blood group phenotyping, leucocyte and platelet serology. The pretransfusion market was the largest segment of the immunohematology market segmented by application, accounting for 40.81% or $1.0 billion of the total in 2024. Going forward, the pretransfusion testing segment is expected to be the fastest growing segment in the immunohematology market segmented by application, at a CAGR of 5.77% during 2024-2029.
The immunohematology market is segmented by end user into blood banks, diagnostic and reference laboratories, hospitals and academic and research institutes. The hospitals market was the largest segment of the immunohematology market segmented by end user, accounting for 39.21% or $963.94 million of the total in 2024. Going forward, the hospitals segment is expected to be the fastest growing segment in the immunohematology market segmented by end user, at a CAGR of 5.67% during 2024-2029.
The top opportunities in the immunohematology markets segmented by product will arise in the reagents segment, which will gain $407.42 million of global annual sales by 2029. The top opportunities in the immunohematology market segmented by technology will arise in the polymerase chain reaction (PCR) segment, which will gain $310.72 million of global annual sales by 2029. The top opportunities in the immunohematology markets segmented by disease will arise in the blood-related diseases segment, which will gain $477.18 million of global annual sales by 2029. The top opportunities in the immunohematology markets segmented by application will arise in the pretransfusion testing segment, which will gain $324.77 million of global annual sales by 2029. The top opportunities in the immunohematology markets segmented by end user will arise in the hospitals segment, which will gain $306.08 million of global annual sales by 2029. The immunohematology market size will gain the most in USA at $241.59 million.
Market-trend-based strategies for the immunohematology market include focus on developing next-generation blood processing systems with cutting-edge automation and focus on transforming blood transfusion management with advanced multiplex analysis.
Player-adopted strategies in the immunohematology market include focus on enhancing its business capabilities through strategic partnerships and focus on strengthening its business operations through new launches.
To take advantage of the opportunities, the analyst recommends the immunohematology companies to focus on developing next-generation blood processing systems, focus on advancing multiplex blood testing technology, focus on the fastest-growing analyzers and systems segment, focus on biochips for accelerated growth, focus on blood-related diseases for market expansion, focus on pretransfusion testing to drive growth, expand in emerging markets, focus on expanding distribution channels for market growth, focus on developing competitive and value-based pricing strategies, focus on digital marketing strategies to enhance brand authority for immunohematology companies, focus on strategic partnerships with key opinion leaders to build credibility for immunohematology companies and focus on hospitals to drive growth in the immunohematology market.
Major Market Trends
- Next-Generation Blood Processing System With Cutting-Edge Automation
- Optimizing Blood Testing Processes With Advanced Multiplex Analysis
Key Mergers and Acquisitions
- Werfen S.a. Acquired Immucor, Inc. to Strengthen Specialized Diagnostics Portfolio
- Quidel Corporation and Ortho Clinical Diagnostics Merger Strengthens Global in Vitro Diagnostics Leadership
Table of Contents
1 Executive Summary
6 Market Characteristics
7 Major Market Trends
8 Immunohematology Market - Macro Economic Scenario
9 Global Market Size and Growth
10 Global Immunohematology Market Segmentation
11 Immunohematology Market, Regional and Country Analysis
12 Asia-Pacific Market
13 Western Europe Market
14 Eastern Europe Market
15 North America Market
16 South America Market
17 Middle East Market
18 Africa Market
19 Competitive Landscape and Company Profiles
22 Key Mergers and Acquisitions
23 Opportunities and Strategies
24 Immunohematology Market, Conclusions and Recommendations
25 Appendix
Executive Summary
Immunohematology Global Market Opportunities And Strategies To 2034 provides the strategists; marketers and senior management with the critical information they need to assess the global immunohematology market as it emerges from the COVID-19 shut down.Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market research findings.
- Benchmark performance against key competitors.
- Utilize the relationships between key data sets for superior strategizing.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis.
Description
Where is the largest and fastest-growing market for immunohematology? How does the market relate to the overall economy; demography and other similar markets? What forces will shape the market going forward? The immunohematology market global report answers all these questions and many more.The report covers market characteristics; size and growth; segmentation; regional and country breakdowns; competitive landscape; market shares; trends and strategies for this market. It traces the market’s history and forecasts market growth by geography. It places the market within the context of the wider immunohematology market; and compares it with other markets.
The report covers the following chapters
- Introduction and Market Characteristics - Brief introduction to the segmentations covered in the market, definitions and explanations about the segment by product, by technology, by disease, by application and by end user.
- Key Trends - Highlights the major trends shaping the global market. This section also highlights likely future developments in the market.
- Macro-Economic Scenario - The report provides an analysis of the impact of the COVID-19 pandemic, impact of the Russia-Ukraine war and impact of rising inflation on global and regional markets, providing strategic insights for businesses in the immunohematology market.
- Global Market Size And Growth - Global historic (2019-2024) and forecast (2024-2029, 2034F) market values and drivers and restraints that support and control the growth of the market in the historic and forecast periods.
- Regional And Country Analysis - Historic (2019-2024) and forecast (2024-2029, 2034F) market values and growth and market share comparison by region and country.
- Market Segmentation - Contains the market values (2019-2024) (2024-2029, 2034F) and analysis for each segment by product, by technology, by disease, by application and by end user in the market. Historic (2019-2024) and forecast (2024-2029) and (2029-2034) market values and growth and market share comparison by region market.
- Regional Market Size and Growth - Regional market size (2024), historic (2019-2024) and forecast (2024-2029, 2034F) market values and growth and market share comparison of countries within the region. This report includes information on all the regions Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa and major countries within each region.
- Competitive Landscape - Details on the competitive landscape of the market, estimated market shares and company profiles of the leading players.
- Competitive Benchmarking - Briefs on the financials comparison between major players in the market.
- Competitive Dashboard - Briefs on competitive dashboard of major players.
- Key Mergers and Acquisitions - Information on recent mergers and acquisitions in the market is covered in the report. This section gives key financial details of mergers and acquisitions which have shaped the market in recent years.
- Market Opportunities And Strategies - Describes market opportunities and strategies based on findings of the research, with information on growth opportunities across countries, segments and strategies to be followed in those markets.
- Conclusions And Recommendations - This section includes recommendations for immunohematology providers in terms of product/service offerings geographic expansion, marketing strategies and target groups.
- Appendix - This section includes details on the NAICS codes covered, abbreviations and currencies codes used in this report.
Markets Covered:
1) By Product: Analyzers And Systems; Reagents2) By Technology: Biochips; Erythrocyte-Magnetized Technology (EMT); Gel Cards; Microplates; Polymerase Chain Reaction (PCR); Other Technologies
3) By Disease: Blood-Related Diseases; HIV (Human Immunodeficiency Viruses); Hepatitis
4) By Application: Pretransfusion Testing; Investigation Of Immune Hemolysis; Perinatal Testing; Blood Group Phenotyping; Leucocyte And Platelet Serology
5) By End User: Blood Banks; Diagnostic And Reference Laboratories; Hospitals; Academic And Research Institutes
Key Companies Mentioned: QuidelOrtho Corporation (Ortho-Clinical Diagnostics); Abbott Laboratories; Grifols S.A.; BIO-RAD LABORATORIES, INC.; Beckman Coulter Inc. (Danaher Corporation)
Countries: China; Australia; India; Indonesia; Japan; South Korea; USA; Canada; Brazil; France; Germany; UK; Italy; Spain; Russia
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets; GDP proportions; expenditure per capita; immunohematology indicators comparison.
Data Segmentation: Country and regional historic and forecast data; market share of competitors; market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Companies Mentioned
The major companies featured in this Immunohematology market report include:- QuidelOrtho Corporation (Ortho-Clinical Diagnostics)
- Abbott Laboratories
- Grifols S.A.
- Bio-Rad Laboratories, Inc.
- Beckman Coulter Inc. (Danaher Corporation)
- BECTON, DICKINSON AND COMPANY
- Cardinal Health Inc.
- Siemens Healthineers
- F. Hoffmann-La Roche AG
- Sysmex Corporation
- Immucor Inc.
- Thermo Fisher Scientific
- Merck KGaA
- Nihon Kohden Corporation
- Hologic, Inc.
- MTC Invitro Diagnostics AG
- Terumo Blood and Cell Technologies (Terumo BCT)
- bioMérieux SA
- EUROIMMUN
- Roche Diagnostics
- Unilabs
- Medsol diagnostics
- Me Cure Healthcare Ltd.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 282 |
| Published | March 2025 |
| Forecast Period | 2024 - 2034 |
| Estimated Market Value ( USD | $ 2.45 Billion |
| Forecasted Market Value ( USD | $ 4.01 Billion |
| Compound Annual Growth Rate | 5.0% |
| Regions Covered | Global |
| No. of Companies Mentioned | 24 |
